Related Experiment Video
Updated: Jun 18, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Correlates of prostate-specific antigen testing in a large multiethnic cohort
Reina Haque1, Stephen K Van Den Eeden, Steven J Jacobsen
1Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, USA. reina.haque@kp.org
The American Journal of Managed Care
|November 10, 2009
Summary
Prostate-specific antigen (PSA) testing rates varied by race and patient factors in California men. Physician discussions significantly increased PSA screening, highlighting their crucial role in prostate cancer screening.
Area of Science:
- Urology
- Public Health
- Health Services Research
Background:
- Prostate-specific antigen (PSA) testing is a key tool for prostate cancer screening.
- Understanding factors influencing PSA testing is crucial for equitable cancer prevention strategies.
Purpose of the Study:
- To examine demographic, clinical, and healthcare-related factors associated with PSA testing uptake.
- To identify predictors of PSA screening in a multiethnic male population.
Main Methods:
- Cross-sectional analysis of 55,278 male health plan members (1998-2002).
- Extraction of laboratory serum PSA values and analysis of demographic and healthcare factors.
- Logistic regression used to estimate odds ratios for PSA testing associations.
Main Results:
- African American men showed higher PSA screening prevalence (82.6%) than white men (73.7%).
- Lower screening rates were linked to Latino ethnicity, lower education, shorter US residency, smoking, and lack of physician discussion.
- African American race and high prostate cancer concern were strong positive predictors of testing.
Conclusions:
- PSA screening disparities exist even in insured populations, influenced by race/ethnicity and patient/clinical factors.
- Healthcare providers play a pivotal role in patient PSA screening decisions.
- Potential inconsistencies in prostate cancer screening guidelines may contribute to observed variations.
